Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

The upper pulmonary veins (PVs) are responsible for the majority of atrial fibrillation (AF) triggering foci, whereas the inferior PVs are more difficult to ablate and prone to postablation ostial ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

Atrial fibrillation is the most common cardiac ... initiated by repetitive discharges originating from the pulmonary veins.

These foci are commonly in the superior pulmonary veins; this is an important factor in the electrophysiologic approach to atrial fibrillation, known as pulmonary vein isolation. Less commonly ...

Aurobindo Pharma Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) to ...

Generic Xarelto is a blood thinner medicine that lowers blood clotting. Aurobindo has obtained the Food and Drug ...

"Second, PFA may yield more durable lesions, thereby reducing pulmonary-vein reconnections ... growing body of evidence supporting the use of PFA for the treatment of atrial fibrillation." "It shows ...